- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Genetic diversity.
Displaying page 1 of 1.
EudraCT Number: 2020-000609-10 | Sponsor Protocol Number: 2020-01-GMF-1 | Start Date*: 2021-07-06 | |||||||||||
Sponsor Name:Center for Surgical Science | |||||||||||||
Full Title: A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery A clinical safety and proof-of-con... | |||||||||||||
Medical condition: A combination of GM-CSF and metronidazole/fosfomycin treatment for pouchitis in Ulcerative Colitis patients after ileal-pouch-anal anastomosis surgery given as an enema or spray in the pouch. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001029-14 | Sponsor Protocol Number: P150949J | Start Date*: 2018-10-25 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic... | |||||||||||||
Medical condition: SCID pediatric patients (n=12 for analysis) requiring an HLA partially compatible allogeneic HSCT. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001144-22 | Sponsor Protocol Number: ML28337 | Start Date*: 2012-07-03 | |||||||||||||||||||||
Sponsor Name:ROCHE SAS | |||||||||||||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA,... | |||||||||||||||||||||||
Medical condition: Epithelial ovarian cancer Fallopian tube carcinoma Primary peritoneal carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006297-23 | Sponsor Protocol Number: 06/Q0701/34 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Guy's & St Thomas' NHS Foundation Trust | |||||||||||||
Full Title: A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy | |||||||||||||
Medical condition: HIV during pregnancy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004011-44 | Sponsor Protocol Number: UofATURRIFIC | Start Date*: 2020-05-20 |
Sponsor Name:The University of Adelaide | ||
Full Title: A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruri... | ||
Medical condition: Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main symptom of this is itching. Ursodeoxycholic acid is routinely used to treat cholestasis but is not... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000584-41 | Sponsor Protocol Number: BP-004 | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:Bellicum Pharmaceuticals, Inc. | |||||||||||||
Full Title: Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders | |||||||||||||
Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005097-19 | Sponsor Protocol Number: EVOLVD | Start Date*: 2019-01-23 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients | ||
Medical condition: Cardiac allograft vasculopathy in de-novo heart transplant recipients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) FI (Completed) SE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
